These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30560935)

  • 41. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
    Jagu S; Kwak K; Schiller JT; Lowy DR; Kleanthous H; Kalnin K; Wang C; Wang HK; Chow LT; Huh WK; Jaganathan KS; Chivukula SV; Roden RB
    J Virol; 2013 Jun; 87(11):6127-36. PubMed ID: 23536682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
    Roth SD; Sapp M; Streeck RE; Selinka HC
    Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
    Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
    Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Heat-shock protein enhances immunogenicity of E7 oncoprotein of human papillomavirus included in chimeric construction (E7 HPV-HSP70)].
    Sveshnikov PG; Solopova ON; Kurbatova EA; Shevchik IuS; Baranovskiĭ PM; Ul'ianov AM; Bokov MN; Kiselev VI
    Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):36-9. PubMed ID: 20734716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26.
    Yu M; Chi X; Huang S; Wang Z; Chen J; Qian C; Han F; Cao L; Li J; Sun H; Zhou L; Li T; Wang Y; Zheng Q; Yu H; Zhang J; Xia N; Li S; Gu Y
    Vaccine; 2022 Oct; 40(42):6141-6152. PubMed ID: 36117002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
    Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
    Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
    Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
    Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Papillomavirus-like particle vaccines.
    Schiller JT; Lowy DR
    J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
    Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
    Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
    Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
    Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.